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ABSTRACT
Background: An increasing number of studies have reported ethnic differences in sunitinib outcome
in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive analysis is still lacking.
Therefore, we systematically collected available published data and performed a meta-analysis to com-
pare sunitinib efficacy and toxicity in Asian and Caucasian mRCC patients.
Methods: Data were extracted from published results from clinical trials, expanded access program
and real-world clinical practice. Progression-free survival (or time to tumor progression), overall survival,
objective response rate and adverse events were used as endpoints to evaluate the differences of suni-
tinib outcome between the two ethnicities. For adverse events, we focused the following clinically rele-
vant side effects: diarrhea, fatigue, mucositis/stomatitis, hand-foot syndrome, hypertension, leukopenia,
neutropenia and thrombocytopenia.
Results: A total of 33 publications including 9977 patients were available for meta-analysis. The effi-
cacy of sunitinib in Asian patients was similar to that in Caucasian patients. However, Asian patients
showed a higher incidence of all grades toxicity of hand-foot syndrome, >grade 2 fatigue, >grade 2
hand-foot syndrome and >grade 2 thrombocytopenia.
Conclusion: Ethnic differences in adverse events of sunitinib in mRCC patients existed and dose adjust-
ment in Asian patients may be considered.
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Renal cell carcinoma (RCC) is the most common type of kid-
ney cancer, accounting for nearly 2% of adult malignancies.
About 25–30% of patients have metastatic spread by the
time they are diagnosed with RCC [1]. During the past two
decades, the therapy for metastatic renal cell carcinoma
(mRCC) has undergone a major evolution. Treatment strat-
egies have changed from interleukin-2 and interferon-alpha
to targeted therapy including tyrosine kinase inhibitors (TKIs,
such as sorafenib, sunitinib, pazopanib, axitinib, cabozantinib
and lenvatinib), mammalian target of rapamycin (mTOR)
inhibitors (temsirolimus and everolimus), and the anti-vascu-
lar endothelial growth factor (VEGF) monoclonal antibody
bevacizumab. More recently, a novel immunotherapeutic
drug, nivolumab, has been added to the armamentarium of
drugs to treat mRCC.
Sunitinib, an oral TKI, is primarily metabolized by cyto-
chrome P450 (CYP) 3A4 into an active metabolite, SU12662.
It received accelerated approval in January 2006 by the Food
and Drug Administration (FDA) for the treatment of mRCC.
The US approval of sunitinib was based on two single-arm,
multicenter studies of single sunitinib treatment in mRCC.
Both trials were conducted in the US, and the percentage of
Caucasian patients in these studies was 94% and 86%,
respectively. In the two studies, sunitinib-treated patients
presented an objective response rate of 25.5% (95% CI
17.5–34.9%) and 36.5% (95% CI 24.7–49.6%) [2].
Subsequently, the European Medicines Agency approved
sunitinib for RCC in 2007, followed by approval for treatment
of RCC in Japan and China in 2008. Sunitinib has become the
first-line treatment for mRCC patients in the US, Europe,
Australia, Japan, South Korea and Taiwan. Due to the strict
reimbursement policies in some Asian countries, sunitinib has
so far not yet been widely used as first-line treatment option
for mRCC patients [3].
Generally, drug trials for market approval are conducted
in western countries first and evaluations in other ethnicities
are performed subsequently. It is well known that for certain
drugs efficacy and toxicity vary greatly among different eth-
nicities. One example is that, in 2005, the FDA approved the
first race-based drug BiDil for the treatment of heart failure
in black patients [4]. Moreover, it was reported that of 167
drugs approved by the FDA between 2008 and 2013, 21%
reported some racial or ethnic differences in pharmacokinet-
ics, safety, efficacy or pharmacogenomics in the label [5].
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Ample examples of ethnic differences in drug response in
the field of oncology are known. Ye et al. [6] compared sora-
fenib outcomes between Chinese and Caucasian RCC
patients. Sorafenib appeared to be more effective in patients
of Chinese ethnicity than in Caucasian patients. However,
Chinese patients more frequently experienced hand-foot syn-
drome. Similarly, ethnic differences in the frequency of axiti-
nib-related hand-foot syndrome were found between
Japanese and Caucasian patients [7].
Until now, differences in sunitinib outcomes among eth-
nicities have been investigated in two studies. In 2013,
Motzer et al. [8] retrospectively collected data from six clin-
ical trials and reported that there was no significant differ-
ence in survival in Caucasian (n¼ 884) versus Asian mRCC
patients (n¼ 70). However, several sunitinib-induced adverse
events such as hand-foot syndrome occurred significantly
more often in Asian patients compared to Caucasian patients
(70% vs. 28%, p< 0.001). In addition, evidence from a global
expanded access program (EAP) with 4371 mRCC patients
reported a comparable sunitinib efficacy between Asian
(n¼ 325) and non-Asian patients (n¼ 4046), and major differ-
ences in the incidence of all grade stomatitis (39% vs. 26%,
Asian and non-Asian patients, respectively), hand-foot syn-
drome (39% vs. 23%), asthenia (12% vs. 22%), and skin dis-
coloration (25% vs. 9%) [9]. Recently, a prospective, post-
marketing study, including 1689 Japanese patients with
mRCC, was performed to investigate sunitinib efficacy and
toxicity in real-world clinical practice. Hand-foot syndrome as
well as thrombocytopenia was observed at higher frequen-
cies and with greater severity in Japanese as compared with
Caucasian patients [10].
Although several studies investigated ethnic differences in
sunitinib efficacy and toxicity, no comprehensive analysis is
available at present. Therefore, we systematically collected
available published data and performed a meta-analysis to
compare sunitinib efficacy as well as toxicity in Asian and
Caucasian mRCC patients.
Materials and methods
Systematic literature search strategy and selection
process
A systematic search for publications archived in MEDLINE,
EMBASE and Web of Science prior to 9 October 2015 was
conducted. A search syntax was compiled by combining
‘renal cell carcinoma’ AND ‘sunitinib’ AND ‘ethnicity’. Various
synonyms and related terms for all subjects were used (the
search syntax is supplied in Supplementary document 1).
Duplicate articles were removed after manual curation.
Initially, articles were scanned by title and abstract. Meeting
abstracts, case reports, reviews and meta-analyses were
excluded. Reference lists were carefully evaluated to identify
additional relevant papers. Only full-text articles published
in English, reporting on efficacy and toxicity in single
sunitinib treatment were included. The treatment had to
consist of an initial regimen of 50mg daily dose (4-week
on/2-week off) or continuous 37.5 daily regimen in mRCC
patients.
Endpoints and data extraction
The primary endpoints of this meta-analysis were progres-
sion-free survival (PFS), objective response rate (ORR, only
complete and partial response have been considered) and
adverse events (AEs) in mRCC patients. Overall survival (OS)
was regarded as secondary endpoint as PFS more closely
reflects drug effects.
From the included articles, the following data were col-
lected: first author, year of publication, sample size, median
age, percentage of males, ethnicity (or country, region), suni-
tinib initial regimen (50mg daily dose with 4/2 schedule or
continuous 37.5mg daily dose), tumor histology, study set-
ting (clinical trial, EAP, real-world clinical practice), prior treat-
ment percentage, ORR, median OS, median PFS (or time to
tumor progression if PFS was not reported), follow-up period,
and incidence of AEs. Based on the existing literature [11],
we focused on the following clinically relevant AEs, i.e., diar-
rhea, fatigue, mucositis/stomatitis, hand-foot syndrome,
hypertension, leukopenia, neutropenia and thrombocyto-
penia. AEs higher than grade 2 as well as all grades of AEs
were obtained.
Statistical analysis
Meta-analysis was performed based on the survival outcomes
coming from the included studies. Individual patient data
were reconstructed from the estimated PFS and OS probabil-
ities. Data in each study consisted of PFS or OS and probabil-
ities every five months for the first two or three years after
treatment. Details concerning the reconstruction of the data
were described in the Appendix (Supplementary document
2). Further technical details were discussed in Fiocco et al.
[12,13]. A multivariate random-effects model for a joint ana-
lysis of survival proportions reported at different times in the
individual studies was used to combine all available informa-
tion in each article included in the meta-analysis on the end-
point of PFS and OS. Moreover, a series of separate meta-
analysis on toxicity data were performed for Caucasian and
Asian patients as well. A random effect model was used to
pool specific proportion in order to estimate an overall pro-
portion and its associated confidence intervals. Inverse vari-
ance method which gives more weight to larger trials was
used to pool outcomes for different studies [14]. All statistical




Our systematic search identified 1514 publications. After
selecting by title, abstract, inclusion and exclusion criteria, 30
articles remained. Manual curation of reference lists identified
three additional papers [15–17]. Finally, a total of 33 publica-
tions, including 9977 patients, were available for meta-analy-
ses [2,8–10,15–43]. Of these 33 publications, 19 were eligible
for survival analyses, 28 for AEs analysis and 20 for ORR.
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Figure 1 represents a flowchart on the study selection
process.
Study characteristics
All studies included were published between 2006 and 2015
(details were provided in Supplementary Table 1). A total of
21 publications included patients from real-world clinical
practice (n¼ 3869), another 11 publications included 1737
patients enrolled in clinical trials, and a large study included
4371 patients who participated in an EAP. In the subgroup of
clinical trials and the EAP, Caucasian patients represent
>90% of the patients. The median age of the patients per
study ranged from 55 to 66 years. Of these patients, more
than 70% were males.
Meta-analysis of sunitinib outcomes between Caucasian
and Asian mRCC patients
The results of the meta-analysis for all grade toxicities in
Asian and Caucasian mRCC patients were displayed in
Figure 2. The incidence of hand-foot syndrome in Asian
patients (52%, 95% CI 45–60%) was found to be two times
higher than that in Caucasian patients (24%, 95% CI
19–29%). Asian and Caucasian patients had a similar
incidence of toxicity other than hand-foot syndrome. Pooled
incidence of toxicities higher than grade 2 was shown in
Figure 3. Asian patients showed a higher percentage of
> grade 2 fatigue, hand-foot syndrome and thrombocyto-
penia of 17 (95% CI 11–13)%, 13 (95% CI 9–17)% and 25
(95% CI 18–32)%, in comparison to Caucasian patients for
whom the results were 8 (95% CI 6–9)%, 5 (95% CI 3–7)%
and 6 (95% CI 2–10)%, respectively. There were no significant
differences of other > grade 2 toxicities.
Figure 4 displayed the estimated pooled mean survival for
PFS and OS in Asian and Caucasian patients, respectively. No
significant difference was found between Asian and
Caucasian patients. For PFS, the hazard ratio for Caucasian
patients was 0.900 (95% CI 0.018–1.345, p-value ¼ 0.280). For
OS, the hazard ratio was 1.330 (95% CI 0.912–1.330, p-value
¼0.314).
Results for ORR were shown by ethnicity and stratified by
setting (clinical trial, EAP and real-world clinical practice); the
results were displayed in Figure 5. ORR for all Asian patients
ranged from 14% to 52.4%, and 14% to 47% for Caucasian
patients. No ORR data could be found in publications includ-
ing Asian patients from clinical trials.
An overview of primary and secondary outcome parame-
ters at individual study level was shown in Supplementary
Tables 2–4.
Discussion
In the current meta-analysis, we systematically collected
available data to compare sunitinib outcomes between Asian
and Caucasian mRCC patients. Our results showed that the
efficacy of sunitinib in mRCC patients from Caucasian and
Asian origin was similar. However, a higher incidence of all
grades hand-foot syndrome, >grade 2 fatigue, >grade 2
hand-foot syndrome and > grade 2 thrombocytopenia was
observed in Asian patients. In addition, we compared the
ORR among three patient settings. The range of ORR of
patients from real-world clinical practice appeared to be
larger than that from the clinical trial setting. However, the
difference of ORR is not as large as we had expected,
because the patients from real-world clinical practice usually
were more heterogeneous than those enrolled in a clinical
trial.
A potential explanation for the observed higher risk of
toxicity in Asian patients may be increased drug exposure. As
to the pharmacokinetics of sunitinib, Houk et al. assessed the
population pharmacokinetics of sunitinib and SU12662
including patients with mRCC, gastrointestinal stromal tumor
and other solid tumors. It was shown that the dug exposure
(indicated as AUC) and the maximal plasma drug concentra-
tion (Cmax) for both sunitinib and SU12662 in Asian patients
were about 15% higher compared to other ethnical groups
[44]. In addition, Nagata et al. [45] reported that the total
trough level of sunitinib in six Japanese RCC patients using
50mg daily 4/2 schedule was higher than 100 ng/ml, whereas
the average concentration of total sunitinib in Caucasian
male patients (body weight: 77 kg, 50mg daily dose) stated
by Houk et al. [44] was 30–90 ng/ml. Of note, in the studies
Figure 1. Flowchart of study selection. The original search on the 9 October
2015 resulted in a total of 1514 publications. Three additional publications were
included based on manual curation of reference lists. In total 1484 publications
were excluded due to duplication (n¼ 580), title and abstract (n¼ 547), data
were not from single sunitinib treatment or included patients with multiple
tumor types (n¼ 349), dosing regimen was not 50mg 4/2 schedule or continu-
ous 37,5mg daily (n¼ 2), duplicate cohort (n¼ 3), only elderly or renal insuffi-
cient or sunitinib treatment more than 1 year patients were included (n¼ 3).
Finally, 33 publications were included in our paper.
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included in our meta-analysis, sunitinib was administrated as
a standard daily dose of 50mg in a 4-week on/2-week off
schedule. Compared to the Caucasian population, Asian peo-
ple in general have a relatively lower body surface area
(BSA), and as a result drug exposure in Asian patients may
be higher after a standard dose. However, no or only a rela-
tively small effect of BSA on sunitinib pharmacokinetics was
identified in both Caucasian [44] and Japanese patients [46].
In contrast, the lean body mass (LBM) has recently been
identified to be related with sunitinib and SU12662 exposure
in 92 patients with solid tumors. The authors reported that
patients with a lower LBM had a higher sunitinib and
SU12662 exposure [47]. Compared to Caucasians, Asian
patients in general have a lower LBM [48], and therefore
might have higher exposure of sunitinib and SU12662.
The ethnic differences in sunitinib pharmacokinetics and
toxicity incidence may at least in part be explained by the
diversity in allele frequencies of variants in genes encoding
enzymes and transporters involved in drug absorption and
metabolism. The association of sunitinib-induced toxicities
with pharmacogenetic determinants was studied by Kim
et al. in 65 Korean mRCC patients [49]. Compared to C-allele
carriers, patients with the AA variant genotype of the drug
transporter ABCG2 rs2231142 had an increased risk for grade
3 or 4 thrombocytopenia, neutropenia and hand-foot syn-
drome [49]. As to the relation of this SNP with
pharmacokinetic parameters, Mizuno et al. clarified the effect
of the ABCG2 rs2231142 genotype in 19 Japanese RCC
patients [50,51]. The clearance/F estimated in A-allele carriers
of rs2231142 was approximately 50% of that in patients
with CC genotype. Compared to CC-genotype patients, the
dose-adjusted AUC0-24 of sunitinib was significantly higher in
A-allele carriers. It was shown that the steady-state plasma
concentrations in A-allele carriers on the daily dose of 25mg
were in the same concentration range (60–80 ng/ml) as seen
in CC-genotype patients on the standard 50mg daily dose. In
another cohort with 66 mRCC patients from France, the asso-
ciation of ABCG2 rs2231142 with sunitinib and SU12662 has
been confirmed [47]. Considering that the variant allele A is
more common in Japanese, Korean and Chinese (about 30%)
than in Caucasian (10%) [52], the ethnic difference in minor
allele frequency (MAF) of this SNP might be an underlying
cause of the higher sunitinib toxicity reported in Asian
patients. In addition, the genetic variant rs776746G>A in
the drug-metabolizing enzyme CYP3A5 is associated with the
defective CYP3A5 expression, resulting in a decreased con-
version of sunitinib into SU12662. It has been reported that
sunitinib exhibited more dermatological toxicities (among
which hand-foot syndrome) compared to SU12662 [53].
Garcia-Donas et al. reported the association of CYP3A53
with toxicity-related dose reduction in 101 Spanish mRCC
patients [54]. CYP3A53 is common is Asian (34%), but rare in
Figure 2. Pooled incidence of all grade toxicities.
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Caucasians (4%), implying the potential effect of this SNP
on the different incidence of hand-foot syndrome between
two ethnical groups. It has been assumed that CYP3A53 is
linked with higher sunitinib exposure. The potential associ-
ation has been explored in Caucasian [55] and Asian mRCC
patients [56]. However, no clear correlations between
CYP3A53 and sunitinib exposure were observed in either
population.
Moreover, a recent retrospective study in 114 Caucasian
patients with sunitinib treatment showed that CYP3A422
(rs35599367 C> T) was associated with decreased sunitinib
clearance [55]. It has been reported that activity of CYP3A4
enzyme is particularly sensitive to dietary effects [57].
Although the potential effect of food on sunitinib pharmaco-
kinetics was not supported by the phase I study in healthy
subjects, in which no difference of sunitinib and SU12662
pharmacokinetics was found between patients with single
dose of sunitinib after either 10-hour fast or a high-fat meal,
the effect of long-term cooking habit, such as the frequently
used CYP3A4-inhibiting spices [58], could not be ignored.
The effect sizes of above-mentioned factors are relatively
small compared to the inter-individual variability of pharma-
cokinetic characteristics of 32.2% and 42.9% in clearance of
sunitinib and SU12662 reported by Diekstra et al. [55], and
even higher variability published by Houk et al. (37.9% and
52.2%, respectively) [44].
Besides the comparison between Asian and Caucasian
patients, an interesting subgroup analysis is the comparison
between Asian patients from Asian sites (Asian-A) and Asian
patients from non-Asian sites (Asian-O) performed by Lee
et al. [9]. It was shown that Asian-O patients had lower inci-
dence of toxicity compared to Asian-A, but had a similar inci-
dence of toxicity as non-Asian patients. This observation
points towards the direction of diet and body weight being
a major determinant of sunitinib toxicity. Indeed, Park et al.
reported that Asians living in the US have a comparable
amount of visceral fat to that of European Americans [59].
Moreover, a meta-analysis showed that visceral fat in
Japanese population was significantly lower than that in
Caucasians [60]. Obviously, visceral fat may modify drug dis-
tribution and thus decrease drug exposure in the tumor [61].
In a real-world clinical setting, reimbursement policies in
different countries may indirectly contribute to ethnic differ-
ences of sunitinib efficacy and toxicity. For example, even
though five agents (sorafenib, sunitinib, everolimus, inter-
feron-alpha and interleukin-2) are currently approved by
Chinese Food and Drug Administration for mRCC treatment,
reimbursement is only available for interferon-alpha and
interleukin-2 [62]. This may imply that sunitinib is more fre-
quently used as a second-line treatment of advanced disease
patients in some Asian countries compared to Caucasian
countries. However, this potential effect does not play a role
Figure 3. Pooled incidence of higher than grade 2 toxicities.
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in our meta-analysis, as no differences in the percentage of
patients with prior treatment from Asian or Caucasian coun-
tries was observed (Supplementary Table 1).
The present meta-analysis pooled all available data from
three different patient settings (clinical trial, EAP and real-
world clinical practice). Due to the strict and homogeneous
patient selection criteria, drug effects in clinical trials may not
be fully representative of real-world clinical practice and data
from various types of drugs suggest the existence of a ‘trial
effect’ [63]. Patients from EAP were those who were not eli-
gible to participate in clinical trials due to exclusion criteria
or were from countries where regulatory approval had not
yet been granted. Therefore, the results from EAP may better
reflect, to some extent, the results found in real-world clinical
practice. Subgroup analyses could give some insight into
inter-setting differences of sunitinib efficacy and toxicity
between ethnicities, but the data available at present do not
allow for performing such subgroup analyses. However, the
comparison of sunitinib efficacy between clinical trial partici-
pants and a matched cohort of non-participants was
explored by Keizman et al., but no significant difference was
observed [63].
Available data indicate that Asian patients more frequently
need a toxicity-related dose reduction or discontinuation
compared to Caucasian patients with 35–76% versus 24–32%,
respectively [20]. It has been suggested that Asian patients
should start their treatment with a lower initial sunitinib
dose. This approach was evaluated in a prospective study
comparing the conventional dose regimen (50mg daily,
4-week on/2-week off) with an attenuated dose regimen
(37.5mg daily, 4-week on/2-week off) in 160 Singapore mRCC
patients. The results showed that patients with attenuated
dose regimen had comparable PFS and OS, but had signifi-
cantly lower incidence of toxicity compared to those with
conventional dose regimen. From this study, it seems that
Asian patients, with a reduced initial dose, have reached a
balance of minimum toxicity and maximum efficacy [20].
The authors would like to point out that this study has
some limitations that ought to be considered. There is a lack
of standard definition of Asian and Caucasian origin, and it is
difficult to designate a multiracial identity. Indeed, the major-
ity of included publications did not report detailed informa-
tion of ethnicity. Even though we contacted the authors of
included studies, no full ethnic data appeared to be available.
Therefore, we decided to regard the patients enrolled in
Asian countries as Asian and patients enrolled in European
and American studies as Caucasian, except when the ethnic
data were presented otherwise. Moreover, although sunitinib
is a standard-of-care treatment in clear cell RCC, it is
acknowledged that efficacy is dependent of histological
tumor type [64]. Therefore, we excluded two papers [25,36]
with a high percentage of non-clear cell RCC patients, from
efficacy analysis.
In conclusion, at a standard dose, Asian patients more fre-
quently experience sunitinib-induced toxicity, such as hand-
foot syndrome, fatigue and thrombocytopenia compared to
Caucasian patients. No significant ethnic difference of suniti-
nib efficacy in mRCC patients was found in the present study.
Figure 4. Pooled progression-free survival (A) and overall survival (B).
Figure 5. Objective response rate (ORR) stratified by setting. NA: not available.
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Therefore, dose adjustment in Asian patients may be
considered.
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